BioElectronics Corporation (OTC: BIEL), a developer of medical technology products, released an update from Chairman Richard Staelin, PhD, highlighting sales growth, cost control, and strategic advancements. The company reported a small profit for calendar year 2025, driven by disciplined cost management including office relocation and staff reductions. Revenue-generating initiatives include targeted advertising campaigns aimed at medical professionals and Generation X consumers to increase awareness of RecoveryRx, a non-opioid pain management device.
The company is expanding outreach to physician-owned ambulatory surgical centers and orthopedic practices to identify a clinical trial partner for RecoveryRx, with the goal of supporting future reimbursement under the federal NO PAIN Act initiative. This initiative is seen as a meaningful long-term opportunity for broader adoption of non-opioid pain management technologies in surgical settings.
Internationally, BioElectronics continues arbitration proceedings in Singapore against a former distributor for breach of contract, working with legal counsel and funders in China to protect intellectual property and shareholder interests.
A key operational milestone is the strategic distribution and licensing relationship with Electrome Corporation. Initial conditions of the supply agreement have been satisfied, with Electrome placing its first purchase order. Manufacturing is underway, and Electrome is planning a commercial launch of BioElectronics' pulsed shortwave therapy products. This partnership provides another pathway to increase consumer awareness and access to FDA-cleared, drug-free pain therapy products.
The company remains focused on clinical market development, direct professional outreach, consumer education, international opportunities, and protection of contractual and intellectual property rights. Staelin expressed confidence in BioElectronics' position within the growing electroceutical and non-opioid pain management markets, emphasizing sustainable growth and long-term value creation for shareholders.
